Anthony Fauci to CD4-Positive T-Lymphocytes
This is a "connection" page, showing publications Anthony Fauci has written about CD4-Positive T-Lymphocytes.
Connection Strength
0.314
-
An open-label phase 1 clinical trial of the anti-a4ß7 monoclonal antibody vedolizumab in HIV-infected individuals. Sci Transl Med. 2019 09 11; 11(509).
Score: 0.068
-
Integrin a4ß7 expression on peripheral blood CD4+ T cells predicts HIV acquisition and disease progression outcomes. Sci Transl Med. 2018 01 24; 10(425).
Score: 0.061
-
A randomized controlled safety/efficacy trial of therapeutic vaccination in HIV-infected individuals who initiated antiretroviral therapy early in infection. Sci Transl Med. 2017 Dec 06; 9(419).
Score: 0.060
-
Treatment with IL-7 prevents the decline of circulating CD4+ T cells during the acute phase of SIV infection in rhesus macaques. PLoS Pathog. 2012; 8(4):e1002636.
Score: 0.041
-
Evaluation of the pathogenesis of decreasing CD4(+) T cell counts in human immunodeficiency virus type 1-infected patients receiving successfully suppressive antiretroviral therapy. J Infect Dis. 2009 Jun 01; 199(11):1648-56.
Score: 0.033
-
Deleterious effect of HIV-1 plasma viremia on B cell costimulatory function. J Immunol. 2003 Jun 15; 170(12):5965-72.
Score: 0.022
-
MAdCAM costimulation through Integrin-a4ß7 promotes HIV replication. Mucosal Immunol. 2018 09; 11(5):1342-1351.
Score: 0.016
-
Early antibody therapy can induce long-lasting immunity to SHIV. Nature. 2017 03 23; 543(7646):559-563.
Score: 0.014